About Megan Blutfield

This author has not yet filled in any details.
So far Megan Blutfield has created 12 blog entries.

White Paper: Developing Advanced Therapies: Considerations for Internal Versus External Manufacturing

2021-04-06T11:17:15-04:00Cell & Gene Therapy, Thought Leadership|

Due to their complexity and cost, developers of cell and gene therapies face unique manufacturing hurdles. Determining the right approach to manufacturing is crucial when bringing these advanced therapeutics from clinical to commercialization.

This white paper, based on a recent webinar co-sponsored by Precision for Medicine and Informa Pharma Intelligence, features the unique expertise of Erin Harris (Editor In Chief of Cell & Gene), David Carr (Director, PRECISIONadvisors), Tony Khoury (Executive Vice President, Project Farma), Janet Lambert (CEO, Alliance for Regenerative Medicine), and Alex Karnal (Partner and Managing Director, Deerfield Management).


Webinar Video: The Great Debate — Internal vs. External Manufacturing for Advanced Therapies

2021-04-01T13:33:16-04:00Cell & Gene Therapy, Events|

Co-hosted by Endpoints Webinars, this panel discussion will address the growing industry concerns regarding manufacturing hurdles unique to cell and gene therapy.  Watch as our panel of experts helps set the landscape for the current state of the advanced therapy sector and share key considerations that go into deciding whether to scale-up manufacturing internally or look to an external supplier like a CDMO.


Precision for Medicine Acquires EganLee, Expands Foothold in the Asia-Pacific (APAC) market


We are excited to announce that EganLee, an Australian-based firm providing a range of clinical trial services for the pharmaceutical, biotechnology, medical device and CRO industries has joined the Precision family! With strong, established relationships with numerous AsiaPac research sites, the acquisition of EganLee expands Precision’s clinical trial footprint in AsiaPac.


Conference Videos: Gene Therapy for Rare Disorders 2021

2021-04-01T11:37:56-04:00Cell & Gene Therapy, Events|

Delivering a gene therapy to market requires a comprehensive and integrated approach. At the 4th annual Gene Therapy for Rare Disorders Conference, Precision ADVANCE participated in a panel discussion, and Precision for Medicine held two clinical presentations, providing crucial insights for clinical development, manufacturing, and commercialization of gene therapies.


How To Calculate Viral Vector Yields: A Critical Component Of The “Make vs Buy” Analysis

2021-03-03T14:49:16-05:00Cell & Gene Therapy, Thought Leadership|

Calculating viral vector yields is essential to determine how much drug product is needed for a specific gene therapy. It’s a critical analysis for any gene therapy organization looking to scale from preclinical to clinical to commercial. Project Farma’s Tony Khoury, Christian Hermanas and Salome Philip provide an in depth review of a valuable yield calculation tool that can serve as a vital prerequisite of the “make vs buy” analysis.


Taking On The Talent Crunch In Biopharma, Cell & Gene Manufacturing

2021-03-08T16:59:46-05:00Cell & Gene Therapy, Thought Leadership|

Although clinical trials in the cell and gene therapy space have skyrocketed, there’s a significant shortfall in the skilled talent required to execute on the exponential potential of cell and gene therapies. Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury discuss the biotherapeutic process and manufacturing talent gap, and propose a multipronged approach to addressing the problem through internal innovation and the external influence of academia and industry associations.


Project Farma: Manufacturing Skills Gap Creates Bottleneck for Cell and Gene Therapy

2021-03-11T09:39:50-05:00Cell & Gene Therapy, Thought Leadership|

The cell and gene therapy manufacturing skills shortage is slowing the abilities of innovative therapies to reach patients, delaying manufacturing scaleup and increasing learning and development costs. Project Farma’s Anshul Mangal discusses the impact of the cell and gene therapy manufacturing skills shortage, and reviews ways to scale up and bring more therapies to commercialization despite the skills gap.


Breaking The Bottleneck For Cell And Gene Therapy Studies: Strategies For Creating Clinical Enthusiasm And Selecting Sites

2021-01-26T11:57:38-05:00Cell & Gene Therapy, Thought Leadership|

A big bottleneck in the evolving field of cell and gene therapy is identifying sites with the capability and capacity to conduct these resource-intensive studies. Gene and cell therapy developers need to create clinical interest to find champions at investigative sites and differentiate their products and clinical trials to keep development moving forward. Precision’s Megan Liles explores strategies for building clinical enthusiasm and selecting the right sites for gene and cell therapy trials.


Precision Medicine Group Secures Major Investment from Blackstone

2020-11-20T08:32:56-05:00Press Releases|

New York, NY & Bethesda, MD — November 20, 2020 — Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, Ethan Leder and Mark Clein, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT, and Vida Ventures.


Load More Posts